News & Events

• Oriva Therapeutics is launched with the support of Asabys, focused on developing innovative therapies in women’s health• The company incorporates two advanced assets from Oncostellae and Medibiofarma, addressing two high-unmet-need chronic conditions in women: endometriosis and uterine fibroids•Sabadell Asabys…

Navarra, Spain – August 28, 2025 — Medibiofarma is pleased to announce the successful completion of the industrial research project titled “Investigation of Novel Agonists of the PPAR-γ Receptor for the Treatment of Crohn’s Disease (PPAR-Crohn)” (Project Code: 0011-1365-2023-000165), co-funded by the…

Crohn’s & Colitis Foundation’s IBD Ventures Awards Investment to Continue their Support for the Development of Medibiofarma’s Novel First-In-Class PPARg Partial Agonist Oral Therapy (MBF-118) for Treatment of Crohn’s Disease Pamplona, Spain / August 25, 2025 / Medibiofarma, a biopharmaceutical…

Palobiofarma and Medibiofarma open new headquarters in the AINbuilding in Cordovilla, Spain · The new facilities, of 200 square meters, consist of an office area next to a fully equipped medicinal chemistry laboratory. In this shared space, both companies will…

Navarra – February 2025 – Medibiofarma S.L., a clinical-stage biotechnology company developinga portfolio of new small molecule therapies announced the award of the European CommissionSeal of Excellence for their clinical asset MBF-015.The project, under the title “Re-Spark – MBF-015. A…

Navarra – February 2024 – Medibiofarma S.L., a clinical-stage biotechnology company developing a portfolio of new therapies for the treatment of neurodegenerative diseases and other pathologies announced the first patient dosed in the Phase IIa clinical trial of MBF-015 in…

Navarra – May 10, 2023 – Medibiofarma S.L., a clinical-stage biotechnology company developing aportfolio of new therapies for the treatment of gastrointestinal (GI) diseases as well as othercancer and non-cancer diseases announced the first patient dosed in the Phase II…

Crohn’s & Colitis Foundation’s IBD Ventures Awards Investment to Support Development of Medibiofarma’s Novel First-In-Class PPARg Partial Agonist Oral Therapy (MBF-118) for Treatment of Crohn’s Disease Pamplona, Spain / March 3, 2023 / Medibiofarma, a biopharmaceutical company developing novel therapies for gastrointestinal diseases and other indications, announced receipt of funding…

Navarra – July 2021– Medibiofarma S.L., a clinical-stage biotechnology company developing, as part of its portfolio of projects, a new disease-modifying therapy for the treatment of neurodegeneration and cognitive decline today announced the first subject dosed in the Phase 1…

Navarra – July 2021– Medibiofarma S.L., a clinical-stage biotechnology company developing a portfolio of new therapies for the treatment of cancer and non-cancer diseases today announced the first subject dosed in the Phase Ib clinical trial of MBF-118. This compound…

Navarra – July 15, 2020 – Medibiofarma S.L., a clinical-stage oncology company developing new immuno-activating therapies for the treatment of cancer today announced the first subject dosed in the Phase 1 clinical trial of MBF-118, a novel covalent partial agonist…

Medibiofarma participated in the “Startup Spotlight” event sponsored by Eli Lilly in the 13th edition of the annual BIO-Europe Spring conference 2019 held in Vienna. Julio Castro, CSO of Medibiofarma, made the presentation of the company in a session that…

Medibiofarma announces the completion of a new financing round of 2 million euros, with the financial support of its founder team and the incorporation of new partners, among them, Sodena, a public investment entity of the Government of Navarre, which…

Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer.  The compound will start IND enabling studies the second quarter 2019.